Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELPIS: Lomecel-B in HLHS
NCT02398604Phase 1Terminated
- Sponsor
- Longeveron
- Start
- Apr 2015
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of laromestrocel in hypoplastic left heart syndrome (HLHS) (2 arms), sponsored by Longeveron. Primary endpoint: Major Adverse Cardiac Events at 1 month. Started Apr 2015; status: terminated.
02
Drugs
laromestrocel
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT02398604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398604.